- Home
- BOF vs TENX Comparison
BOF vs TENX Comparison
Compare BOF & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BOF | TENX |
|---|---|---|
| Founded | 2017 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.4M | 56.2M |
| IPO Year | 2023 | 2001 |
Fundamental Metrics
Financial Performance| Metric | BOF | TENX |
|---|---|---|
| Price | $4.32 | $13.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $29.67 |
| AVG Volume (30 Days) | 49.7K | ★ 467.2K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.33 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,184,018.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 258.20 | N/A |
| 52 Week Low | $1.65 | $5.09 |
| 52 Week High | $4.95 | $18.38 |
Technical Indicators
Market Signals| Indicator | BOF | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 56.74 | 45.96 |
| Support Level | $2.79 | $12.71 |
| Resistance Level | $4.95 | $14.15 |
| Average True Range (ATR) | 0.30 | 1.04 |
| MACD | 0.06 | -0.19 |
| Stochastic Oscillator | 67.90 | 14.42 |
Price Performance
Historical ComparisonAbout BOF BranchOut Food Inc.
Branchout Food inc is engaged in the development, marketing, sale, and distribution of plant-based, dehydrated fruit and vegetable snacks and powders. Its products are currently manufactured for the company by contract manufacturers based in South America and North America that produce dehydrated fruit and vegetable products for the company using a new proprietary dehydration technology that it licenses from a third party. The Company's customers are located throughout the United States. Its current primary products are BranchOut Snacks, BranchOut Powders, and BranchOut Industrial Ingredients.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.